Stratos Wealth Partners’s PDL BioPharma, Inc. PDLI Stock Holding History

Stratos Wealth Partners’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,300	Closed	-$6K	–	3023
2018 Q3	$6K	Buy	+2,300	New	+$5.64K	﹤0.01%	2421
2018 Q2	–	Sell	-2,300	Closed	-$7K	–	3133
2018 Q1	$7K	Hold	2,300	–	–	﹤0.01%	2517
2017 Q4	$6K	Buy	+2,300	New	+$7.07K	﹤0.01%	2371

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Stratos Wealth Partners's PDLI Position: Q4 2018 in Review

Stratos Wealth Partners sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 2,300 shares — an estimated $6K sold.

Stratos Wealth Partners first reported a position in PDLI in Q4 2017 and held it in 3 quarters. The position peaked at $7K in Q1 2018. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Stratos Wealth Partners reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Stratos Wealth Partners sold 2,300 PDL BioPharma, Inc. shares in Q4 2018, an estimated $6K.
Stratos Wealth Partners first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 3 quarters.
Stratos Wealth Partners's PDL BioPharma, Inc. position peaked at $7K in Q1 2018.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.